Timolol maleate and HDL cholesterol after myocardial infarction

Area of Science:

• Cardiology
• Pharmacology

Background:

• Cardiovascular disease remains a leading cause of mortality worldwide.
• Beta-blockers like timolol are commonly prescribed post-myocardial infarction.
• The impact of beta-blockers on lipid profiles requires further investigation.

Purpose of the Study:

• To analyze the effect of long-term timolol treatment on plasma lipids.
• To assess the prognostic significance of high-density lipoprotein (HDL) cholesterol levels after myocardial infarction.
• To determine if lipid changes influence timolol's cardioprotective effects.

Main Methods:

• Analysis of plasma lipid levels in patients from the Norwegian timolol multicentre study.
• Comparison of HDL cholesterol levels between timolol and placebo groups over one year.
• Evaluation of total mortality rates in relation to HDL cholesterol levels and timolol treatment.

Main Results:

• One-year timolol treatment significantly reduced HDL cholesterol levels (1.32 to 1.26 mmol/l).
• Timolol-treated patients had lower HDL cholesterol than placebo patients after one year (1.26 vs 1.32 mmol/l).
• HDL cholesterol levels post-myocardial infarction showed no prognostic importance for mortality.
• Timolol reduced mortality in both low (24%) and high (43%) HDL cholesterol groups.

Conclusions:

• Timolol treatment leads to a decrease in HDL cholesterol levels.
• The reduction in HDL cholesterol by timolol does not diminish its beneficial effect on reducing mortality after myocardial infarction.
• Timolol's cardioprotective effects are maintained despite alterations in lipid profiles.